Neupogen (filgrastim) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The neupogen (filgrastim) market size has grown strongly in recent years. It will grow from $1.4 million in 2025 to $1.48 million in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to growth in chemotherapy utilization, high infection risk in neutropenic patients, clinical validation of g-csf therapy, hospital-centered cancer care, limited early treatment options.

The neupogen (filgrastim) market size is expected to see strong growth in the next few years. It will grow to $1.81 million in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing cancer incidence, expansion of biosimilar adoption, growth in outpatient oncology services, improved access to biologic therapies, focus on infection prevention. Major trends in the forecast period include rising use of supportive care in oncology, expansion of chemotherapy-induced neutropenia management, increased adoption of biologic growth factors, shift toward outpatient neutropenia treatment, growing use of biosimilar alternatives.

The increasing prevalence of various diseases is expected to drive the growth of the Neupogen (filgrastim) market in the coming years. Diseases are disruptions in the structure or function of the body that produce specific symptoms or affect certain areas, often caused by infections, genetics, environmental factors, or lifestyle choices. The rising occurrence of these conditions is fueled by factors such as aging populations, sedentary lifestyles, higher pollution levels, poor dietary habits, and the global spread of infectious pathogens. Neupogen (filgrastim) helps manage complications from chemotherapy-induced neutropenia by stimulating neutrophil production, thereby enhancing the immune system’s ability to fight infections in immunocompromised patients. It plays a key role in reducing hospitalizations, managing infection risks, and supporting uninterrupted cancer treatment regimens for patients undergoing intensive therapies. For example, in April 2024, Allergy UK, a UK-based national charity, reported that over 21 million people in the UK were affected by allergies, making it the most commonly reported chronic condition in 2022, with projections suggesting that by 2026, half of Europe’s population will experience at least one allergy. Additionally, in June 2022, Macmillan Cancer Support, a UK-based cancer charity, reported that 3 million people were living with cancer in the UK in 2022, with projections reaching nearly 3.5 million by 2025 and 4 million by 2030. Therefore, the rising prevalence of various diseases is driving the Neupogen (filgrastim) market.

Government initiatives in healthcare research and development are also expected to support the growth of the Neupogen (filgrastim) market. Such initiatives refer to targeted actions, programs, policies, or projects undertaken by governmental bodies at local, regional, national, or international levels to address specific healthcare needs and drive positive outcomes. Several governments are implementing programs to support aspects of Neupogen (filgrastim) development and use. For example, in May 2023, the UK Department of Health and Social Care announced a $749.09 million (£650 million) “Life Sci for Growth” package to boost the life sciences sector. This package included $139.44 million (£121 million) to accelerate commercial clinical trials, $177.47 million (£154 million) to expand the UK Biobank’s capabilities, and incentives of up to $288.11 million (£250 million) to attract pension-fund investment into the sector. Therefore, government initiatives for research and development in healthcare are driving the Neupogen (filgrastim) market.

Leading companies in the Neupogen (filgrastim) market are increasingly developing innovative filgrastim biosimilars to offer cost-effective and accessible alternatives for treating chemotherapy-induced neutropenia. Filgrastim biosimilars are biologic medicines that closely replicate the original Neupogen in terms of safety, efficacy, and structure, primarily used to stimulate neutrophil production in chemotherapy patients to prevent neutropenia. For instance, in September 2024, Tanvex BioPharma, a US-based biopharmaceutical company, received FDA approval for Nypozi (filgrastim-txid), a biosimilar referencing Amgen’s Neupogen. Nypozi was one of three biosimilars approved by the FDA on the same day, contributing to a total of 55 biosimilars cleared in the United States as of June 2024. It is indicated to reduce the incidence of infection, as evidenced by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs.

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neupogen (filgrastim) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the neupogen market by increasing costs for imported biologic raw materials, formulation inputs, and cold-chain transport systems. These pressures have affected hospital and retail pharmacy pricing, especially in regions reliant on imported biologics. Asia-pacific and latin america are among the most affected regions due to limited domestic production capacity. However, tariffs have supported local biosimilar manufacturing, encouraged supplier diversification, and strengthened long-term supply continuity.

The neupogen (filgrastim) market research report is one of a series of new reports that provides neupogen (filgrastim) market statistics, including neupogen (filgrastim) industry global market size, regional shares, competitors with a neupogen (filgrastim) market share, detailed neupogen (filgrastim) market segments, market trends and opportunities, and any further data you may need to thrive in the neupogen (filgrastim) industry. This neupogen (filgrastim) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neupogen (filgrastim) is a recombinant granulocyte colony-stimulating factor (G-CSF) that promotes the production of white blood cells in the bone marrow. It is used to prevent infections in patients with neutropenia caused by chemotherapy, bone marrow transplantation, or certain medical conditions.

The main forms of Neupogen (filgrastim) are biologic and biosimilar. Biologic drugs are produced from living organisms and involve complex manufacturing processes to achieve specific therapeutic effects. Its indications include chemotherapy-induced neutropenia, chronic neutropenia, and other related conditions. Neupogen is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The neupogen (filgrastim) market consists of sales of formulations, pre-filled syringes, vials for injection, and long-acting pegylated G-CSF derivatives. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.